Jakub Svoboda, MD

• Non-Hodgkin Lymphoma
• Hodgkin Lymphoma

My research interests focus on improving outcomes in patients with lymphomas using novel agents and immune based therapies. I have served as the principal investigator on several trials including multicenter investigator initiated trial using brentuximab (immunoconjugate) in combination with chemotherapy as frontline treatment for CD30+ B cell lymphomas. I have also conducted a pilot trial using chimeric antigen receptor (CAR) T cells in patients in relapsed/refractory Hodgkin lymphoma and served as co-investigator on trials using CAR T cells in non-Hodgkin lymphomas. More recently, I have been involved in collaborative work with our translational scientists which may allow us to find new therapeutic targets for cellular therapies in Hodgkin lymphoma.